Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 29 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 8771696

    Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2014 · Expires Jul 3, 2034

    granted

  2. US 8765125

    Methods of treating autoimmune diseases with Dll4 antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2014 · Expires Jun 26, 2034

    granted

  3. US 8735095

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted May 27, 2014 · Expires May 22, 2034

    granted

  4. US 8710004

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 29, 2014 · Expires Apr 24, 2034

    granted

  5. US 8692052

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted

  6. US 8658154

    Humanized FcγR mice

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2014 · Expires Feb 20, 2034

    granted

  7. US 8658853

    Low affinity FcγR deficient mice

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2014 · Expires Feb 20, 2034

    granted

  8. US 8647842

    Methods for producing a fusion protein capable of binding VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 11, 2014 · Expires Feb 6, 2034

    granted

  9. US 8642741

    Human antibodies to human TNF-like ligand 1A (TL1A)

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2014 · Expires Jan 30, 2034

    granted

  10. US 8637031

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2014 · Expires Jan 23, 2034

    granted

  11. US 8613927

    High affinity human antibodies to human nerve growth factor

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted

  12. US 8597898

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted

  13. US 8586713

    Readily isolated bispecific antibodies with native immunoglobulin format

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 19, 2013 · Expires Nov 14, 2033

    granted

  14. US 8568721

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted

  15. US 8545847

    Human antibodies to the human glucagon receptor and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted

  16. US 8541646

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted

  17. US 8518887

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 27, 2013 · Expires Aug 22, 2033

    granted

  18. US 8501184

    High affinity human antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted

  19. US 8481046

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 9, 2013 · Expires Jul 4, 2033

    granted

  20. US 8470324

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 25, 2013 · Expires Jun 20, 2033

    granted

  21. US 8445434

    IGF-1 fusion polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 21, 2013 · Expires May 16, 2033

    granted

  22. US 8425907

    Methods for treating pruritus by administering an antibody that specifically binds human PAR2

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  23. US 8414876

    Methods of using IL-1 antagonists to treat autoinflammatory disease

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  24. US 8414890

    Human antibodies to human RANKL, encoding nucleic acids and methods of treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.